Genpact secondary risk is minimal, says RW Baird Baird expects shares of Genpact to be weak following its announcement of a secondary offering. The firm believes the ongoing secondary risk is minimal and views the company risk/reward as favorable citing its strong management team, execution, and potential upside to Q4 estimates. Shares are Outperform rated with a $20 price target.
NASCO and Genpact announces partnership to reimagine US healthcare NASCO and Genpact announced they will partner in an innovative effort to address the business operations needs of healthcare plans in the continually evolving U.S. healthcare market. NASCO and Genpact will transform health plan administration into a digitally-powered operating model that surrounds and extends NASCO's established, extremely efficient and scalable technology platform.